A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00073151. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Study identification
- NCT ID
- NCT00073151
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Jan 2006 (Actual)
- Last update posted
- Nov 29, 2007
2003 – 2006
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oncology Hematology Group of South Florida | Miami | Florida | — | — |
| Florida Cancer Institute | New Port Richey | Florida | — | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637-1460 | — |
| University of Maryland Greenbaum Cancer Center | Baltimore | Maryland | 21201-1595 | — |
| Oncology & Hematology Associates of Kansas City, PA | Kansas City | Missouri | 64111 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110-1093 | — |
| Albany Regional Cancer Center | Albany | New York | — | — |
| Raleigh Hematology Oncology | Cary | North Carolina | — | — |
| Dayton Oncology and Hematology | Kettering | Ohio | — | — |
| Cancer Care Associates | Oklahoma City | Oklahoma | — | — |
| Cancer Centers of the Carolinas | Greenville | South Carolina | — | — |
| West Cancer Clinic | Memphis | Tennessee | 38120 | — |
| Texas Oncology | Dallas | Texas | — | — |
| Texas Oncology | Fort Worth | Texas | — | — |
| Cancer Care Northwest | Spokane | Washington | — | — |
| Northwest Cancer Specialists | Vancouver | Washington | — | — |
| University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin | 53792-5666 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00073151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2007 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00073151 live on ClinicalTrials.gov.